DimLeb
Member
- Jun 20, 2021
- 358
- Tinnitus Since
- 03/2021
- Cause of Tinnitus
- Idiopathic Cochleopathy or Maybe Loud Music
No, they presented the results from the SPI-1005 Phase 2 in June 2019 (the trial lasted between September 2017 - March 2019):I have no idea, and I was going through the beginning of this thread.
They passed the Phase 2 for ear problems in 2013.
What happened? I don't know too much about this drug or company. I'm guessing the Phase 3 failed? And the drug is being used for COVID-19 and other diseases. Then if it comes out we can try it. Just like the Hough Ear Institute pill, which is now called OKN-007.
SEATTLE, Nov. 5, 2013 /PRNewswire/ -- "Sound Pharmaceuticals (SPI) has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod®and insert earphones."No, they presented the results from the SPI-1005 Phase 2 in June 2019 (the trial lasted between September 2017 - March 2019):
Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial
According to their pipeline they are either still preparing for Phase 3 or are in it now, hard to tell from the graphic on their website. The last news they gave us about it was in June 2020:
Sound Pharmaceuticals advances pivotal Phase 3 clinical trials in Meniere's Disease
But yeah, I'd also like some more updates from this company.
You're right, my bad. I completely missed that they were doing SPI-1005 for acute, mild to moderate NIHL too. I thought it was only for Meniere's (and now COVID-19). It's still listed on their pipeline chart and stuck between Phase 2 and 3. It's really strange it hasn't moved forward if Phase 2 was successful so long ago.SEATTLE, Nov. 5, 2013 /PRNewswire/ -- "Sound Pharmaceuticals (SPI) has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod®and insert earphones."
Go look on page one of this thread. Instead of Meniere's it was for hearing loss. They did a Phase 2 in 2013. It was Nick's post. But yeah this company is pretty confusing.
Yeah so strange. This drug is good to fall back on. Definitely better than nothing. I'm not gonna put all hopes on it.You're right, my bad. I completely missed that they were doing SPI-1005 for acute, mild to moderate NIHL too. I thought it was only for Meniere's (and now COVID-19). It's still listed on their pipeline chart and stuck between Phase 2 and 3. It's really strange it hasn't moved forward if Phase 2 was successful so long ago.
I too won't put a ton of hopes on this one.Yeah so strange. This drug is good to fall back on. Definitely better than nothing. I'm not gonna put all hopes on it.
Yea, well said. I'm lucky because my tinnitus is not horrible. I can live with it. My distortions that beep can be horrible but it's not always bad. The hyperacusis is killin me. Severe pain hyperacusis is not fun at all. Makes me wanna die. I hope it improves with time.I too won't put a ton of hopes on this one.
I'm most hopeful about Susan Shore's device to be honest. But that is not a guarantee, and I cannot wait for these things for the rest of my life.
For now I will focus on self-improvement and controlling what I can control. I'm putting my effort into meditation, occasional fasting, daily cold-showers, grounding, avoiding processed foods and salicylate high foods, consuming fermented foods and raw meat, getting lots of sunlight, exercising, preventing further damage, and just living life as best as I can.
Not Phase 3 but this poster was in Phase 1 and 2 for Meniere's and posted about it in the Frequency Therapeutics thread. Check out his posts:Anyone on here taking part in their Meniere's Phase 3 or COVID-19 Phase 2?
Nice spot.Phase 3 started!
Sound Pharma initiates enrollment in pivotal Phase 3 clinical trial of SPI-1005 for the treatment of hearing loss and tinnitus in Meniere's disease
And for the record, it is a one year study. Second year is for additional safety points. They can prepare FDA approval after the primary checkpoints.
That would be one year + 3 months of prep for FDA + 4 months for approval due to fast track. Early 2024 we can beg our ENTs for SPI-1005/Ebselen instead of Prednisone after noise exposure. Not sure if the long term "brain" tinnitus will benefit.
From the article:I wonder if this has potential for those not suffering from Meniere's disease?
The take home for me is that it improved hearing loss at low frequencies and thus reduced tinnitus loudness.In the Phase 2b study, clinically relevant improvements were observed in low frequency hearing by PTA and WIN scores at 8 weeks after the start of SPI-1005 when compared to placebo. The percentage of subjects showing significant auditory improvements using PTA (≥10 dB gain at one low frequency) in the SPI-1005 400 mg BID dose group rose from 47% at 4 weeks to 61% at 8 weeks, while the percentage showing significant improvements in WIN (≥20% increase in word recognition) rose from 57% at 4 weeks to 68% at 8 weeks. Additionally, SPI-1005 treatment also significantly reduced tinnitus perception or tinnitus loudness (TL) when compared to placebo (p < 0.05). Reductions in TL averaged 1.4 pts in the 400 mg group vs 0.7 pts in the placebo group (30% reduction vs 10% reduction, p <0.02). These Phase 2b data confirmed an initial finding from the Phase 1b trial, that SPI-1005 can reduce tinnitus loudness by clinically relevant levels. These improvements in auditory function further support the use of SPI-1005 to treat sudden sensorineural hearing loss, noise-induced hearing loss, and age-related loss, other indications where hearing loss and tinnitus are prominent features.
It's good news, just pointing out what it is designed to do.I'm here to enjoy the brief moment of feeling fantastic about this update before the negative Nancy's come in to select anything from this list:
- this will never work because <insert reason X>
- this study is flawed because <insert reason Y>
- etc
So no improvement in high frequencies as Meniere's only affects the low frequencies?The take home for me is that it improved hearing loss at low frequencies and thus reduced tinnitus loudness.
This is what you would expect of a treatment for Meniere's disease, where key characteristic is low frequency hearing loss that fluctuates.
I'm quoting from the company's website. I understand that Meniere's is classified by low frequency hearing loss, tinnitus and episodic vertigo.So no improvement in high frequencies as Meniere's only affects the low frequencies?
I don't think @Ben Winders was referring to your post, @Nick47.It's good news, just pointing out what it is designed to do.
He wasn'tI don't think @Ben Winders was referring to your post, @Nick47.
There is no treatment. It is in a clinical trial and may still fail.there's now a treatment for Ménière's disease. Amazing.
Counting my chickens, sure. It's in Phase 3 and they've had impressive results thus far. I think this one gets through.There is no treatment. It is in a clinical trial and may still fail.
So it will not help high frequency tinnitus? And would this drug help long term tinnitus sufferers?So no improvement in high frequencies as Meniere's only affects the low frequencies?